News Releases

September 24, 2019
Urovant Sciences Reports Positive Long-Term Data from the Double-Blind Extension of the Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder
    Vibegron further improved treatment benefit on key overactive bladder (OAB) symptoms over the 40-week extension period       41% of patients on vibegron became “dry,” defined as having no urge urinary incontinence episodes at week 52       Vibegron demonstrated a favorable long-term safety and
Additional Formats
September 6, 2019
Urovant Sciences Parent Company, Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create Broad Strategic Alliance
Sumitomo Dainippon Pharma is expected to fully assume Roivant’s ownership interest of Urovant Sciences (approximately 75% of outstanding Urovant shares); definitive agreement expected by the end of October 2019 Sumitomo Dainippon Pharma is a top-ten Japanese listed multi-national pharmaceutical
Additional Formats
August 13, 2019
Urovant Sciences Reports 2019 First Fiscal Quarter Financial Results
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Aug. 13, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the 2019 first fiscal
Additional Formats
August 6, 2019
Urovant Sciences to Report 2019 First Fiscal Quarter Financial Results
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Aug. 6, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will report 2019 first fiscal quarter
Additional Formats
June 3, 2019
Urovant Sciences to Present at Annual Roivant Pipeline Day
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Jun. 3, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for urologic conditions, today announced Chief Executive Officer Keith A.
Additional Formats
Displaying 1 - 10 of 21